Infectious Disease Research Institute

Rna vaccines - rna vaccines have been shown To be critical tools for combatting pandemics and have been safely administered To billions of people across the globe. Aahi's rna vaccine platform is distinct from existing licensed rna vaccines in that it is based on a self-amplifying rna technology and delivered by a flexible nanostructured lipid carrier. Together, these features mean that the vaccine could be stockpiled for years, delivered at room temperature, and more rapidly manufactured To address future pandemics. Aahi scientists are advancing rna vaccines against covid-19, influenza, yellow fever, zika, chikungunya, and hiv, and adapting the platform To be delivered by nasal spray or directly administered into tumors.

Manufacturing and clinical support - aahi's in-house manufacturing capabilities support rapid scale-up and production of vaccines for use in phase 1 and phase 2 clinical trials and complete aahis's unique vaccine discovery-development process. Aahi's Research scientists and formulations/process development teams work with aahi's manufacturing experts To develop manufacturing processes To produce vaccine candidates under controlled conditions so that they are suitable for use in human studies. This enables aahi To quickly and efficiently move a vaccine from late-stage Research To early phase clinical studies. Aahi consults later stage clinical studies. Aahi's manufacturing suite follows us fda "good manufacturing practice" regulations and is an invaluable resource To aahi scientists and biotechnology developers in the non-profit, academic, and for-profit sectors.

Formulations - adjuvants are powerful immune-stimulating molecules that increase the efficacy of vaccines and enhance the immune system's ability To destroy tumors. Aahi has among the largest porfolios of adjuvants; importantly, aahi scientists formulate these molecules in a way that makes them minimally toxic and maximally potent. In partnership with vaccine developers across the world, many aahi adjuvant formulations have been safely administered To thousands of people in rigorous clinical trials. Aahi's adjuvant formulations now are in leading vaccine candidates against hiv, tuberculosis, malaria, and a myriad of other Infectious diseases.

Process and product development - modern vaccines are increasingly complex and their design needs To be tailored To specific target product profiles To ensure practical accessibility. Sustainable sourcing of raw materials, streamlined manufacturing methods, and temperature stability are critically important To enable vaccines for global Health applications in resource-limited settings. Alternative routes of administration, such as intranasal delivery, not only may best be suited To fight respiratory pathogens but also help To address vaccine hesitancy and To increase vaccine uptake. Aahi scientists are world-experts at developing processes and methods To advance novel products that meet the needs of vaccine developers both within aahi and externally among the dozens of academic, non-profit, and commercial partners.